


This Report was generated using the valuation tools available on [StockCalc.com](#). For a free 30 day trial click [here](#).

Save

Close Price/Date  
\$153.02 (USD) 12/21/2020

Weighted Valuation  
\$149.72 (USD)

Overall Rating  
Fairly valued to slightly **Overvalued** by 2.2%




Valuation Models (in order of importance)	Comparables: \$126.94 (USD) Adjusted Book Value: \$123.01 (USD) Multiples: \$138.99 (USD)
Valuation Methods	This company is:
Cash Flow:	<b>Undervalued</b> on a Cash Flow Valuation
Comparable Company:	<b>Overvalued</b> on a Comparable Valuation
Asset:	<b>Overvalued</b> on an Asset Valuation
According to Analyst consensus at \$166.20 this stock is <b>Undervalued</b>	

This Stock is	Technically		
Fundamentally	Buy	Hold	Sell
Under Valued	Buy the Stock	Buy or Wait on Technical	Wait on Technical
Fairly Valued	Buy or Wait on Fundamental	Wait on Both Indicators for Direction	Sell or Wait on Technical
Over Valued	Wait on Fundamental	Sell or Wait on Fundamental	Sell the Stock

Company Overview (JNJ:NYS USD)	
Price	153.02
Range	150.05 - 153.41
52 week	111.14 - 155.51
Open	152.01
Vol / Avg.	7.69M/8.62M
Mkt cap	394.62B
P/E	23.57
Div/yield	3.75/0.03
EPS	5.63
Shares	2.63B
Beta	0.68

**Company Description**

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.



We have up to 6 valuation points for each company. Details are at the bottom of the report.

Discounted Cash Flow and Sensitivity Analysis for JNJ:NYS

Using a discounted cash flow model we generated an intrinsic value of **\$201.95 (USD)** for **JNJ:NYS**

Sensitivity Analysis

(showing how changes in the input variables impact the DCF calculation)

JNJ:NYS	Current Values	Valuation If Dropped *		Valuation If Raised *	
Calculated Value:	\$201.95	1%	5%	1%	5%
WACC (or Ke)	5.30	\$255.66		\$166.15	
Terminal Growth Rate	0.30	\$169.51		\$250.60	
Tax Rate	0.13	\$213.14		\$190.75	
Cash Flow	32,798,701,800	\$191.28		\$212.61	
Capital Expenditures	-3,427,200,000	\$200.94		\$202.95	
Long Term Debt	26,989,000,000	\$202.46		\$201.43	

\* Changes are absolute: ex WACC from 8% to 7%

Comparables Model

Using similar companies and price based ratios we generated a valuation of **\$126.94 (USD)** for **JNJ:NYS**. We also generated a valuation of **\$141.21 (USD)** using other metrics and comparables. The comparable companies were Amgen (AMGN:NAS), Gilead Sciences (GILD:NAS), Pfizer (PFE:NYS), Merck & Co (MRK:NYS) and AbbVie (ABBV:NYS).

Company JNJ:NYS	End Date Value	Price Based on Comps	Adjustment Factor (%)
Earnings/Share	\$6.36 (USD)	\$180.65 (USD)	21.0
Book Value/Share	\$24.49 (USD)	\$187.75 (USD)	-57.2
Sales/Share	\$30.27 (USD)	\$128.65 (USD)	-5.1
Cash Flow/Share	\$8.08 (USD)	\$96.61 (USD)	-6.7
EBITDA/Share	\$9.23 (USD)	\$143.07 (USD)	-14.2

JNJ:NYS	Ratios Used	Average Values	AMGN:NAS	GILD:NAS	PFE:NYS	MRK:NYS	ABBV:NYS
24.06	PE Ratio	28.40	18.32	59.73	24.12	17.50	22.35
6.25	PB Ratio	7.67	12.08	4.21	3.18	6.87	11.99
5.06	PS Ratio	4.25	5.40	3.19	4.32	4.26	4.08
18.93	PCF Ratio	13.24	12.42	8.36	16.76	18.28	10.36
15.54	EV to EBITDA	15.50	11.95	19.11	17.01	12.28	17.16

Multiples

Using a multiples approach we generated a valuation of **\$138.99 (USD)** for **JNJ:NYS**

Company JNJ:NYS	End Date Value	Price Based on Comps	Adjustment Factor
Earnings/Share	\$6.36 (USD)	\$145.54 (USD)	0
Book Value/Share	\$24.49 (USD)	\$133.21 (USD)	0
Sales/Share	\$30.27 (USD)	\$141.54 (USD)	0
Cash Flow/Share	\$8.08 (USD)	\$139.68 (USD)	0
EBITDA/Share	\$9.23 (USD)	\$134.96 (USD)	0

Ratios	Ratio Average
PE Ratio	22.88
PB Ratio	5.44
PS Ratio	4.68
PCF Ratio	17.28
EV to EBITDA	14.62

Adjusted Book Value versus Historical Price to Book

The average the Price to Book ratio for **JNJ:NYS** for the last 10 years was **5.02**. We ran the Adjusted Book Value for **JNJ:NYS** and generated a book value of **\$24.49 (USD)**. By multiplying these we get an adjusted valuation of **\$123.01 (USD)**

Analyst Data

In the Stockcalc database there are 5 analysts that provide a valuation for **JNJ:NYS**. The 5 analysts have a consensus valuation for **JNJ:NYS** for 2021 of **\$166.20 (USD)**.

Analyst Recommendation					
Buy	Hold	Sell	Rating (of 5)	Guidance	As Of
4	3	0	4.1429	Outperform	2020-12-18

Current Price: 153.02 USD

Analyst Consensus			
USD Millions	2020	2021	2022
Mean EPS	7.98	9.07	9.73
# EPS Analysts	7	7	3
Mean Revenue	81,440.60	87,996.70	91,567.00
# Revenue Analysts	4	4	3
Mean Target Price	166.20		
Mean Cash Flow	7.88	9.90	11.00
Mean EBITDA	27,099.10	30,734.80	32,700.60
Mean Net Income	20,424.80	23,164.80	24,746.70
Mean Debt Outstanding	7,190.40	-2,891.50	-17,349.20
Mean Tax Rate			
Mean Growth Rate	5.95		
Mean Capital Expenditure	3,580.00	3,810.20	3,784.80

## Explanation of Valuation Models

We have up to 6 valuation points for each company in the database.

The **Discounted Cash Flow (DCF)** valuation is a cash flow model where cash flow projections are discounted back to the present to calculate value per share. DCF is a common valuation technique especially for companies undergoing irregular cash flows such as resource companies (mining, forestry, oil and gas) going through price cycles or smaller companies about to generate cash flow (junior exploration companies, junior pharma, technology firms...).

The **Price Comparables** valuation is the result of valuing the company we are looking at on the basis of ratios from selected comparable companies: Price to Earnings, Price to Book, Price to Sales, Price to Cash Flow, Enterprise Value (EV) to EBITDA. Each of these ratios for the selected comparable companies are averaged and multiplied by the values for the company we are interested in to calculate a value per share for our selected company.

We have included the **Other Comparables** as a way to value companies that cannot be valued using Earnings based ratios. This technique is very useful for companies still experiencing negative cash flows such as mining exploration firms. We use Cash/Share, Book Value/Share, MarketCap, 1 Year Return, NetPPE as the ratios here. Each of these ratios for the selected comparable companies are averaged and multiplied by the values for the company we are interested in to calculate a value per share for our selected company.

**Multiples** are similar to Price comparables where we look at current or historic ratios for the company in question to assess what it should be worth today based on those historic ratios. We use the same 5 ratios as in the price comparables and value the company with its historic averages.

With **Adjusted Book Value (ABV)** we calculate the book value per share for the company based on its balance sheet and multiply that book value per share by its historical price to book ratio to calculate a value per share.

If we have **Analyst coverage** for the company we use the consensus target price here.

## Notice to User

*This Report was generated using the tools available on [StockCalc.com](https://stockcalc.com). Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal [disclaimer](#).*

*The contents of this report and the Stockcalc website are provided on an “**as is**” or “**as available**” basis with all faults and may not be current in all cases. The information in this report or on the website is subject to continuous change and Patchell Brook Equity Analytics Inc. assumes no responsibility to update or amend such information or that the information will be current. Patchell Brook Equity Analytics Inc. does not claim that all information, calculations or opinions presented in this report or on its website are true, reliable, or complete. Accordingly, you should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment or other decision. Any information, data, opinions, calculations or recommendations provided by third parties through links to other websites or otherwise made available through this report or website are solely those of the third party and not of Patchell Brook Equity Analytics Inc. Please refer to the Terms of Use on [stockcalc.com](https://stockcalc.com) for further information. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc [here](#).*